Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals - Wikidata - awgldk - TriplyDB

Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals

Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals

http://www.wikidata.org/entity/Q35800195

about

Bone Marrow Gene Therapy for HIV/AIDS Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice Engineering T Cells to Functionally Cure HIV-1 Infection CD4(+) T Cells Modified by the Endoribonuclease MazF Are Safe and Can Persist in SHIV-infected Rhesus Macaques In vivo safety and persistence of endoribonuclease gene-transduced CD4+ T cells in cynomolgus macaques for HIV-1 gene therapy model Selection and characterization of human immunodeficiency virus type 1 mutants that are resistant to inhibition by the transdominant negative RevM10 protein Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes.Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev A role for KH domain proteins (Sam68-like mammalian proteins and quaking proteins) in the post-transcriptional regulation of HIV replication.Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein.Ongoing trials of immune-based therapies for HIV infection in adults.Genetically modified immunocompetent cells in HIV infection.A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells.Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.Genetic therapy for HIV/AIDS.Is gene therapy a good therapeutic approach for HIV-positive patients?CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer Genetic therapies against HIV.Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.CCR5 as a natural and modulated target for inhibition of HIV.Novel cell and gene therapies for HIV.Practical considerations in gene therapy for HIV cure.Potential mechanisms for cell-based gene therapy to treat HIV/AIDS.Personalized gene therapy locks out HIV, paving the way to control virus without antiretroviral drugs.Engineered T cell therapies.Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors.A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment).Gene therapy for HIV infections: Intracellular immunization.A self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression in genetically engineered T-cells.Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.Cell and Gene Therapy for HIV Cure.RNA Interference Therapies for an HIV-1 Functional Cure.Single-step, multiple retroviral transduction of human T cells Genetic Strategies for HIV Treatment and Prevention

P2860

Q26801765-294356D8-9C2C-403E-9B7D-A1FFAD6240D6 Q27022347-49272189-9D70-4B49-BF77-1160270638BC Q28086801-BEB0439D-18AC-40C0-AFC7-7D9A0F4EC624 Q28656393-F6DB3B3C-970A-40CB-AD6C-7C5D30B65ECB Q28741350-168C6CE4-A040-4231-824C-EE6222A86DAB Q30304057-CB20351D-9FCA-4278-9DE9-98D8FE47B51D Q33688441-7FC74B18-82EA-4819-9DD6-5546EB0933B9 Q33851112-EE4F74E3-2791-4A9B-AE2D-DFF768080B53 Q33956386-84DA94CB-90D7-4E9E-B2D1-0CA243CE40C1 Q34353375-53235814-2D96-4EE6-A38A-F7176E7111B2 Q34451967-55439EE0-5D6C-4B30-836F-02000AAC16CA Q34564279-D40EB971-2C99-4C40-9E73-5D6DF0E6EA2B Q35191116-8D79B891-4C79-43A4-BD78-45C4DBE9B2E0 Q35202343-87C93B08-7E02-45E5-9BD4-EE6DA896001F Q35207524-C3E6F3C2-707D-44F2-A787-7CAD99E6256A Q35663424-27912F8C-21EC-4BB5-967D-8F77B28B62E5 Q36235825-89941D00-CA12-41D4-B867-2D0FD3568A64 Q37027170-5F129EAA-8675-4A11-9D09-F2E7D72F84D9 Q37363070-6A7EA930-24BC-4BA9-B4C7-546A60424CD5 Q37373008-F084F432-C2BD-4AA3-8CE9-15BDC088E428 Q37566693-93FF4A68-2050-49A9-8839-74E69F2C6C06 Q38048762-AE766F63-BE2B-4E8E-8BBD-3EB5FF452D8F Q38180645-243FA42F-7003-4BBE-89D1-CB8F42C0F02B Q38267240-7908227D-400D-46F2-B657-8F076C9A9E57 Q38462651-EA725760-587A-4103-B647-A616D6762355 Q38623827-B91CF446-AF57-43DE-9059-2124B37F59BC Q39203103-D09A900C-FABD-40A1-989D-E4AE6A10D9B4 Q39214476-36C5E439-8A3C-42C3-862F-09D71090A72F Q39683830-BF0BC57B-3573-41B2-8C0D-6FAEBC513909 Q40138988-45A27A34-4AC6-44C4-B999-0541D51489B0 Q40205976-C410470B-01B8-4DBD-AE7B-DA7B6E89EFBB Q40739621-AA1028DD-8EEE-40E0-9214-6305C575DAFD Q47236016-C3ED7CFB-11AA-41CF-9896-6492A5914079 Q47252129-835A8EE2-BDAB-4AEB-9364-905F098E934B Q57351531-C869AB46-9A05-42E2-A617-437F4C541F89 Q58604627-65B5F658-229E-4CDB-9DFE-ACAC647B2209

P2860

Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals

http://www.wikidata.org/entity/Q35800195

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

Enhanced T cell engraftment af ...... ne in HIV-infected individuals

@ast

Enhanced T cell engraftment af ...... ne in HIV-infected individuals

@en

type

label

Enhanced T cell engraftment af ...... ne in HIV-infected individuals

@ast

Enhanced T cell engraftment af ...... ne in HIV-infected individuals

@en

prefLabel

Enhanced T cell engraftment af ...... ne in HIV-infected individuals

@ast

Enhanced T cell engraftment af ...... ne in HIV-infected individuals

@en

P1433

Q35800195-3B92F17E-0180-4E6F-BB93-B64C01D418B1

P1476

Q35800195-7492A382-AC2B-4DC4-A5A2-26FBFDA40192

P2093

Q35800195-07AC2402-CEAF-4A4A-8BCB-8910446BC71F

Q35800195-1940A614-1E97-4B74-9A51-EC13CD709818

Q35800195-1F506F6F-67C6-44D4-A347-7018B20AF422

Q35800195-2CDF0509-B54D-4DBD-8DD1-134FA78DA038

Q35800195-41EB8CDD-A5B4-4F9D-9A78-3A57B375A27B

Q35800195-74B56EB5-ACC7-4922-98D1-C18791AEB21C

Q35800195-9A5FD361-64BD-4E04-A5B1-6E485E8A4043

P2860

Q35800195-0DAAF4AA-5E42-4A92-8D0A-CF985D99A1CE

Q35800195-1BAB5D0F-EFEB-4B3C-B99F-44E0475AA038

Q35800195-1FFA086E-C483-4393-9F92-534562C7ECE7

Q35800195-2D553836-8D46-4B90-8C5E-618868B5CC15

Q35800195-3200FBBD-E562-4DF6-B7EB-114F4438F4AF

Q35800195-3A4C83A9-B9A0-4D1F-8CA1-6F0633F64DE1

Q35800195-5071D086-D705-489F-A3FA-7419DDF84325

Q35800195-5706B19D-A271-44AD-9518-1C40E5856519

Q35800195-5AD15A9A-B88A-4728-9A64-ED6B883B491E

Q35800195-5AE54236-A585-4DA5-8F57-0F0053B9B5BF

P304

Q35800195-4286DB74-FB62-45D7-BF8F-E605CE046042

P31

Q35800195-F57513E1-2E36-475B-8E22-F755D046FEB4

P356

Q35800195-40161FFA-361D-416C-ABD9-CF0CC3F01BFE

P407

Q35800195-A5F61989-D41C-416F-8F0B-0A021E272409

P433

Q35800195-88CB6A40-31F5-48FF-9BD0-393D4CB736E1

P478

Q35800195-EF65EA9E-BCDF-4879-A2F4-DD798D89A376

P577

Q35800195-7D9ED35B-7087-42E0-A429-904BCA26BE4D

P5875

Q35800195-21846BB3-8A7B-4F67-B7CF-C2C690A2D263

P698

Q35800195-200369C8-AA73-4CD6-B8B0-A0E407BD6AB4

P932

Q35800195-883841AD-A38A-42F7-B95F-65AB1A74594F

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Enhanced T cell engraftment af ...... ne in HIV-infected individuals

@en

P2093

C H June

http://www.w3.org/2001/XMLSchema#string

C Woffendin

http://www.w3.org/2001/XMLSchema#string

D K Bishop

http://www.w3.org/2001/XMLSchema#string

G J Nabel

http://www.w3.org/2001/XMLSchema#string

L Xu

http://www.w3.org/2001/XMLSchema#string

S Verma

http://www.w3.org/2001/XMLSchema#string

U Ranga

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins

Cellular protein modulates effects of human immunodeficiency virus type 1 Rev

Regulation of human immunodeficiency virus env expression by the rev gene product

Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation

A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1

The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA

rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA

HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency

A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.

Mutational definition of the human immunodeficiency virus type 1 Rev activation domain.

P304

1201-1206

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.95.3.1201

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

1998-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13783021

http://www.w3.org/2001/XMLSchema#string

P698

9448309

http://www.w3.org/2001/XMLSchema#string

P932

18718

http://www.w3.org/2001/XMLSchema#string